Use of stem-cell derived endothelial cells for disease relevant cell modeling and drug discovery
This record is part of
a dataset collected by the EU Commission in June-September 2018
. Some of these links will therefore die out with time.
Please see the
overview of courses maintained by ETPLAS
or contact Norecopa for more information.
United States of America
15 November 2018
|Description:||ABSTRACT: The use of human pluripotent stem cells (hPSCs) for in vitro disease-modeling is limited by the lack of robust and efficient protocols for the differentiation of relevant adult cell types. Previously, we have reported a method to generate vascular endothelial cells from hPSCs (Patsch et al. Nat Cell Biol. 2015). This novel and robust protocol in conjunction with use of programmed nucleases allows generation of relevant endothelilal cell disease models. We will show examples of modeling high-barrier resistance endothelial cells in vitro, by generation of CLDN5 reporter and use of chemical profiling, and modeling the effect of a severe metabolic genetic disease (AKT2 loss-of-function or dominant active mutation) on endothelial cells.|
Optional / Voluntary
Students, Researchers, Regulators and policy-makers, Teachers and educators, Scientific officers / Project managers
Academia, Industry, Governmental bodies, Contract Research Organizations (CROs), Consulting, SMEs
Continuing Professional Development, University (Master), University (Doctoral education), Postdoctoral (teaching and research)
In vitro methods
Full coverage (a dedicated course)
Did you find what you were looking for?Yes, I found it! No, I did not!
Thanks for your feedback! Please note that we cannot reply to you unless you send us an email.
What are you looking for?
We value your feedback so we can improve the information on the page. Please add your email address if you would like a reply. Thank you in advance for your help.!Please contact us by email if you have any questions.